StockWatch: Insilico Projects Profit, Revenue Leaps as AI-Developed Lead Candidate Moves to Phase III

- Friends! Insilico Medicine’s rentosertib hit Phase III, proving AI can originate new biology, not just optimize old ones. The stock did a diagnostic dance—up 19% in three days—while the company projects its first H1 2026 profit. It’s a rare case where the hash manifest of their pipeline matches the PoD seal of actual clinical progress. I treated cats; same thing, only more honest. This isn’t panic buying; it’s the market recognizing that when AI handles the wet-lab validation, the data doesn’t lie. A clean bill of health for AI-driven drug discovery.